Quick Answer
Summit Therapeutics Inc. reported Operating Income of -$226.00 million for fiscal year 2024.
Summit Therapeutics Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$226.00M | +62.9% |
| 2023 | -$609.65M | -745.7% |
| 2022 | -$72.09M | +16.4% |
| 2021 | -$86.19M | -62.0% |
| 2020 | -$53.19M | -93.6% |
| 2019 | -$27.47M | -609.8% |
| 2019 | $5.39M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | -$58.38M | -184.9% | +2.1% |
| June 30, 2024 | -$59.62M | -277.5% | -40.6% |
| March 31, 2024 | -$42.39M | +92.1% | -106.9% |
| September 30, 2023 | -$20.49M | -21.0% | -29.7% |
| June 30, 2023 | -$15.79M | -24.4% | +97.1% |
| March 31, 2023 | -$537.15M | -2324.2% | -3070.9% |
| September 30, 2022 | -$16.94M | +13.1% | -33.5% |
| June 30, 2022 | -$12.69M | +46.5% | +42.7% |
- Summit Therapeutics Inc. showed an increase of +62.9% in Operating Income compared to the prior fiscal year.
- Over the 2019–2024 period, Summit Therapeutics Inc.’s operating income has declined by 4293.7% (from $5.39 million to -$226.00 million).
- The most recent figure is from Summit Therapeutics Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on February 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: